Statement on lanreotide in the U.S.
- 20 December 2021 - 1 mins read
![Statement on lanreotide in the U.S. Statement on lanreotide in the U.S.](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2021/12/05105825/202105_Images_346x346pix_3.jpeg)
PARIS, FRANCE, 20 December 2021 – 6:00 PM CET – Ipsen has learned that Cipla Limited and its subsidiary Cipla USA, Inc. has received final approval of a lanreotide product from the U.S. Food and Drug Administration; the FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway. There is no change to Ipsen’s mid-term financial outlook to 2024